Disclose material study design/methodology factors

AI-verifiedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

FDA recommends that aspects of study design and methodology material to accurately interpreting the presented data (e.g., study type, objectives, dosage/regimen used, controls, patient population studied) be clearly and prominently disclosed.

Check

Identify which aspects of the underlying study's design and methodology are material to interpreting the claim presented (type of study, study objectives, dosage/use regimen, controls used, patient population studied are the examples FDA gives), then check that those aspects are disclosed clearly and prominently. Omission of a design detail that is not material to interpreting the claim is not a violation.

Escalate when

It is unclear which design factors are material to interpretation for a given claim.

Where this comes from

Q.8/A.8, bullet 1 · page 17. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…he following are some high-level recommendations for firms to consider when developing their presentations of information in CFL promotional communications to help ensure the presentations do not mislead the applicable audience(s): Any study results or other data and information that are relied upon to support a firm’s CFL promotional communication should be accurately represented in the communications. Moreover, aspects of study design and methodology that are material for audiences to accurately interpret the information presented (e.g. type of study, study objectives, product dosage/use regimens, controls used, patient population studied) from any studies relied on should be clearly and prominently disclosed in firms’ CFL promotional communications, and material limitations related to the study design, methodology, and results should also be disclosed in a clear and prominent manner. The CFL promotional communication should accurately characterize and contextualize the relevant information about the product, including by disclosing unfavorable or inconsistent findings. For example, if a firm presents efficacy results from a postmarketing study of its produc…

Open the original at page 17 on fda.gov ↗Read our full copy →

Document: FDA guidance: Medical Product Communications that Are Consistent With the FDA-Required Labeling – Questions and Answers (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: 1a18b7f242bfbbf897f198df…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

Basisconsistent-with-labeling

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The substance is supported by A.8 bullet 1: 'aspects of study design and methodology that are material for audiences to accurately interpret the information presented (e.g. type of study, study objectives, product dosage/use regimens, controls used, patient population studied) from any studies relied on should be clearly and prominently disclosed in firms' CFL promotional communications.'
- The stored quote is truncated mid-sentence at 'should be' and therefore omits the very words the Rule relies on — 'clearly and prominently disclosed in firms' CFL promotional communications.' As stored, the evidence does not carry the 'clearly and prominently' element or the CFL scope of the rule statement.
- Scope is broader than the source, for the same reason as US-DISC-001: A.8's recommendations are stated to apply only to CFL promotional communications, but applies_when has no basis limiter.
- The Check reads as a mandatory five-item checklist ('Check whether the piece discloses study type, objectives, dosage/regimen, controls, and population studied'). The source makes these illustrative examples ('e.g.') of aspects that are disclosed when material for accurate interpretation; as written the Check invites findings against pieces that omit an item that is not material. The trailing 'where material to interpreting the claim' is too easy to miss.
- Treated as one requirement (disclose the material design/methodology aspects), so atomic. 'Judgment' is right — materiality and 'clear and prominent' are impression/prominence questions, and the source's footnote 25 describes prominence in terms of conspicuousness, location, font size, contrast and white space. 'Guidance' and the locator are correct; 'warning' is defensible.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is a self-contained clause of the second sentence of Q.8/A.8 bullet 1, retaining its subject ('aspects of study design and methodology that are material...') and its predicate ('should be clearly and prominently disclosed'); it stops cleanly before the separate limitations clause rather than running into unrelated text.
- Supported and not overstated: the rule states it as an FDA recommendation, keeps FDA's illustrative list as examples ('e.g.') rather than a closed checklist, and does not extend the obligation beyond CFL promotional communications.
- Atomic: one requirement — clear and prominent disclosure of material design/methodology aspects. The limitations requirement from the same sentence is correctly split out into a separate rule.
- Determinism 'judgment' is right twice over: materiality to audience interpretation and 'clear and prominent' both turn on impression and prominence (footnote 25 describes prominence as a conspicuousness assessment).
- Authority 'guidance' matches the source; applies_when, locator and 'warning' severity are all defensible, and the check correctly notes that omitting a non-material design detail is not a violation.

Nearby rules

US-DISC-001 US-DISC-003